Clarity Pharmaceuticals Ltd

ASX:CU6 Voorraadrapport

Marktkapitalisatie: AU$2.4b

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Clarity Pharmaceuticals Beheer

Beheer criteriumcontroles 3/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Colin Biggin

Algemeen directeur

AU$1.0m

Totale compensatie

Percentage CEO-salaris43.5%
Dienstverband CEO5yrs
Eigendom CEO1.0%
Management gemiddelde ambtstermijn5yrs
Gemiddelde ambtstermijn bestuur4.8yrs

Recente managementupdates

Recent updates

We Think Clarity Pharmaceuticals (ASX:CU6) Can Easily Afford To Drive Business Growth

Sep 23
We Think Clarity Pharmaceuticals (ASX:CU6) Can Easily Afford To Drive Business Growth

Companies Like Clarity Pharmaceuticals (ASX:CU6) Are In A Position To Invest In Growth

Jan 03
Companies Like Clarity Pharmaceuticals (ASX:CU6) Are In A Position To Invest In Growth

We're Interested To See How Clarity Pharmaceuticals (ASX:CU6) Uses Its Cash Hoard To Grow

May 29
We're Interested To See How Clarity Pharmaceuticals (ASX:CU6) Uses Its Cash Hoard To Grow

Companies Like Clarity Pharmaceuticals (ASX:CU6) Are In A Position To Invest In Growth

Aug 24
Companies Like Clarity Pharmaceuticals (ASX:CU6) Are In A Position To Invest In Growth

Here's Why We're Not Too Worried About Clarity Pharmaceuticals' (ASX:CU6) Cash Burn Situation

Jan 13
Here's Why We're Not Too Worried About Clarity Pharmaceuticals' (ASX:CU6) Cash Burn Situation

Analyse CEO-vergoeding

Hoe is Colin Biggin's beloning veranderd ten opzichte van Clarity Pharmaceuticals's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

-AU$42m

Mar 31 2024n/an/a

-AU$36m

Dec 31 2023n/an/a

-AU$31m

Sep 30 2023n/an/a

-AU$28m

Jun 30 2023AU$1mAU$444k

-AU$25m

Mar 31 2023n/an/a

-AU$23m

Dec 31 2022n/an/a

-AU$21m

Sep 30 2022n/an/a

-AU$23m

Jun 30 2022AU$811kAU$347k

-AU$24m

Mar 31 2022n/an/a

-AU$21m

Dec 31 2021n/an/a

-AU$19m

Sep 30 2021n/an/a

-AU$15m

Jun 30 2021AU$907kAU$308k

-AU$10m

Mar 31 2021n/an/a

-AU$9m

Dec 31 2020n/an/a

-AU$9m

Sep 30 2020n/an/a

-AU$8m

Jun 30 2020AU$657kAU$303k

-AU$7m

Compensatie versus markt: De totale vergoeding ($USD 704.40K ) Colin } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de Australian markt ($USD 1.47M ).

Compensatie versus inkomsten: De vergoeding van Colin is gestegen terwijl het bedrijf verliesgevend is.

CEO

Colin Biggin

5yrs

Tenure

AU$1,020,674

Compensatie

Dr. Colin David Biggin, Ph D., has been Managing Director, Chief Executive Officer and Executive Director at Clarity Pharmaceuticals Ltd since October 1, 2019. Dr. Biggin joined Clarity Pharmaceuticals Pty...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Alan Taylor
Executive Chairman10.9yrsAU$1.22m4.62%
A$ 112.1m
Colin Biggin
MD, CEO & Executive Director5yrsAU$1.02m1.03%
A$ 24.9m
David Green
Chief Financial Officer2.5yrsAU$273.61kgeen gegevens
Shaemus Gleason
Executive Vice President of Operationsno datageen gegevensgeen gegevens
Matthew Harris
Chief Scientific Officerno dataAU$241.43k1.92%
A$ 46.5m
Lisa Sadetskaya
Director of Corporate Communications.no datageen gegevensgeen gegevens
Mary Bennett
Head of Human Resourceno datageen gegevensgeen gegevens
Michelle Parker
Chief Clinical Officerno datageen gegevens0.17%
A$ 4.1m
Othon Gervasio
Chief Medical Officerno datageen gegevensgeen gegevens
Robert Vickery
Company Secretaryno dataAU$268.69kgeen gegevens

5.0yrs

Gemiddelde duur

Ervaren management: Het managementteam van CU6 is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5 jaar).

Bestuursleden

NaamPositieTenureCompensatieEigendom
Alan Taylor
Executive Chairman10.9yrsAU$1.22m4.62%
A$ 112.1m
Colin Biggin
MD, CEO & Executive Director5yrsAU$1.02m1.03%
A$ 24.9m
Christopher Roberts
Non-Executive Director8.6yrsAU$86.88k5.67%
A$ 137.4m
Thomas Ramdahl
Non-Executive Director5.6yrsAU$86.88k0.16%
A$ 4.0m
Jon Stoner
Member of Scientific Advisory Board1.7yrsgeen gegevensgeen gegevens
Neal Shore
Member of Scientific Advisory Board2.4yrsgeen gegevensgeen gegevens
Rosanne Robinson
Lead Independent Director14yrsAU$95.72k0.056%
A$ 1.4m
Jason Lewis
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Oliver Sartor
Member of Scientific Advisory Board4.6yrsgeen gegevensgeen gegevens
Paul Donnelly
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Andrei Iagaru
Member of Scientific Advisory Board2.5yrsgeen gegevensgeen gegevens
Louise Emmett
Member of Scientific Advisory Board2.3yrsgeen gegevensgeen gegevens

4.8yrs

Gemiddelde duur

68yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van CU6 wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.8 jaar).